7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.
about
Molecular cloning of the cDNA coding for mouse aldehyde oxidase: tissue distribution and regulation in vivo by testosterone.High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.Delaying surgery with chemotherapy for osteosarcoma of the extremities.Biochemical and pharmacological consequences of the interaction between methotrexate and ketoprofen in the rabbit.Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidaseHigh-dose methotrexate-associated acute renal failure may be an avoidable complication.Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.Purification, cDNA cloning, and tissue distribution of bovine liver aldehyde oxidase.Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin.Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.Preventing and Managing Toxicities of High-Dose MethotrexateGlucarpidase following high-dose methotrexate: update on development.Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology.Practical issues with high dose methotrexate therapy.Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion.Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate.Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.Protection of cells from methotrexate toxicity by 7-hydroxymethotrexate.Development and application of a radioimmunoassay for methotrexate.Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Renal toxicity and chemotherapy in children with cancer.Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate.
P2860
Q31813048-E059D169-1F8F-46F8-A31B-CDF42FC92F2AQ35640471-2E5DFCA7-085E-4809-BE32-041E6EAC5053Q35784014-D9B06571-9F8A-41C0-B064-5EE511F7D29FQ35982202-DEA76738-178C-41CD-ACB7-59E95BB32067Q36072102-170F0C3E-3EB5-4019-B997-89FBF7188825Q36330820-C65D3697-3A2F-44EC-8032-6175BCC5D4C7Q36492327-BAE90D41-2F64-45F3-A30D-79E02AA79198Q36694435-01467C36-F34B-419F-8619-CF5AC04FD5F9Q36788353-77DEC27D-0349-4237-9778-ACD673976223Q36896845-CC25C796-9581-4E8F-9745-D37C10F764BDQ37093674-337C1C57-22D3-4653-9FA1-6FE54E762CF7Q37496637-468C9212-8080-47E5-B27C-7067A39229E1Q37635158-2A105947-7124-403E-BCB8-6C363B3814A6Q37929894-74A5B85A-2770-4361-BF02-B817816FFCAFQ37951561-D300D8BE-73CC-4914-9289-418B8496B01DQ38243780-FB3B0DDE-EB88-459A-8CA9-E774D3A671AFQ38844526-058D0EB3-7B17-4D89-9851-E0778BA0D248Q39780182-6DD675F7-FA14-46AF-8F3C-9CFAF54F2555Q39911676-41A6BA43-18D5-48D7-A848-CC57D9F712A5Q40177601-599D7663-8434-49D6-96A6-6B17B1A721E1Q41444080-7A588F6A-9D31-4624-96BE-F41D4D23F585Q41489289-99D3F55C-D7DA-4B9A-9B64-C1CF4C610C6CQ42374596-2D6E5AEE-303C-4644-B3C4-5B3838352061Q42578636-00CBB010-71A3-4288-87C6-640253F2C17AQ44281596-DB684E94-77C6-411C-A8EC-40468BE0F8D3Q46446111-A09F054B-7910-4479-B46F-D37786CAD03CQ48321401-A5EA32FB-C265-4855-B7ED-337AFA030CE5Q48933623-DB219A60-07DC-46B4-8E20-84C1327620B3Q51350287-899B4648-094B-413A-8A41-F4FD86E4A13BQ52541503-705AADDB-C8A9-433F-9CB6-811B4E2052F6
P2860
7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.
description
1976 nî lūn-bûn
@nan
1976 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1976 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
name
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@ast
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@en
type
label
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@ast
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@en
prefLabel
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@ast
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@en
P2093
P2860
P356
P1476
7-Hydroxymethotrexate as a uri ...... eiving high dose methotrexate.
@en
P2093
P2860
P304
P356
10.1172/JCI108308
P407
P577
1976-02-01T00:00:00Z